Summary We describe melphalan pharmacokinetics in 26 patients treated by isolated limb perfusion (ILP). Group A (n = 11) were treated with a bolus of melphalan (1.5 mg kg-'), and in a phase I study the dose was increased to 1.75 mg kg-'. The higher dose was given as a bolus to Group B (n = 9), and by divided dose to Group C (n = 6).
The rationale for isolated limb perfusion (ILP) in the management of cancer depends on the generation of high levels of effective anticancer agent confined to the tumourbearing limb, thereby avoiding unacceptable systemic toxicity.
It is clearly important to establish whether the complex and expensive technique of ILP genuinely achieves its major aim i.e. maximum levels of melphalan in the tumour-bearing limb and minimum systemic exposure. ILP is effective in the management of locally advanced malignant melanoma, and may be an effective adjuvant to surgery for thick, high risk primary lesions. Having reviewed our early experience of patients treated by ILP, it was confirmed that, because of the absence of melphalan-induced toxicity, there was scope for a phase I (dose escalating) clinical study.
The study of pharmacokinetics is concerned with the absorption, distribution, biotransformation and excretion of drugs (Goodman et al., 1985) . For a given dose these factors govern the concentration of drug at the site of action and they determine how the concentration varies with time.
We have studied melphalan pharmacokinetics in the context of a phase I study of ILP.
The aims of our studies were:
(1) to measure melphalan concentrations in perfusate during ILP, and compare these with the levels in the systemic circulation during and after perfusion, (2) to study the pharmacokinetics of melphalan in ILP, as the dose was increased in a phase I study, (3) to compare the pharmacokinetics of bolus dose with divided dose administration.
Patients, materials and methods
Patient groups
Only patients having external iliac perfusion for malignant melanoma were included in the study. The starting dose of melphalan was 1.5 mg kg' body weight, which is the maximum dose recommended in the protocols on which our technique is based (Krementz et al., 1987; Schraffordt Koops et al., 1981) . We planned that the dose would be escalated by increments of 0.25 mg kg-' body weight. Pharmacokinetic data was acquired on a total of 26 consecutive patients. The three main groups were:
A. Eleven patients who had isolated limb perfusion with a melphalan dose of 1.5 mg kg-' body weight, given by a single bolus injected into the venous line, B. Nine patients who had isolated limb perfusion with a melphalan dose of 1.75 mg kg-' body weight, given by a single bolus (as Group A), and C. Six patients who had standard isolated limb perfusion except for the melphalan dose of 1.75mgkg-' body weight, which was injected into the venous line in three aliquots, at 0, 15 and 30 min during perfusion. Group B comprises patients in the second stage of our phase I study.
Groups C patients were treated with the same dose as Group B, but it was given in divided amounts for comparison of the pharmacokinetic profile with that of Group B. This was done because divided dose administration was advised in the protocol of a Medical Research Council trial of adjuvant isolated limb perfusion.
Local Ethical Committee approval was granted for all studies described here.
Clinical ILP With induction of general anaesthesia 1.5 grams of cefuroxime is given intravenously. A radial arterial line is inserted for per-operative monitoring and for repeated systemic blood sampling. Thermistor skin probes (Yellow Springs) are applied to the skin of the affected limb, and the temperatures are continuously displayed per-operatively on a monitor screen (Siemens Sirecust). A stockingette (Tubigrip) on the leg, and gamgee round the foot protect the skin from direct contact with a heated water blanket (Hawksley Ripple-Heat system with custom blanket) which is then wrapped around the limb, and enclosed in sterile drapes.
Under routine balanced general anaesthesia the external iliac vessels are exposed retro-peritoneally via an oblique incision in the iliac fossa. When the isolated circuit is stable (after 3 -5 min) 5 ml of 20% fluorescein is injected into the perfusate and, using a portable ultra-violet lamp, the absence of a significant 'leak' from the leg to the systemic circulation is confirmed by close inspection of the skin above and below the tourniquet.
When the calf skin temperature is at least 37.5°C melphalan is administered as a bolus of 1.5-1.75mg kg-' of body weight (iliac perfusion). Melphalan assay by HPLC The sensitive and specific HPLC assay which we used is based on an established method (Chang et al., 1978b) . 10 gIg of dansyl proline (Sigma) is added to a one millilitre or less portion of the thawed plasma sample. In the analysis dansyl proline acts as an internal standard, a substance which is chemically similar to melphalan (the losses of which parallel the losses of melphalan) but which generates a distinct peak on the mobile phase at 1.5 ml/min to a 250 x 4 mm stainless steel column (Waters), packed with giBondapak C 18 (Waters). The elution buffer consists of 50 ml 0.01 M NaH2PO4 and 50 ml methanol titrated to pH 3.0 with phosphoric acid (BDH, Analar Grade) .
Eluted melphalan and dansyl proline were detected by a UV detector (Model LC-UV, Pye Unicam) set at 261 nm wavelength. The UV spectrophotometer range was 0.01 or 0.02 A.U. The recorder was set at 1 mv and the chart run at 10 cm h'.
The data were processed by a recorder-integrator (Model DP88, Pye Unicam) which measures the areas under peaks on the elution chromatogram. The tR (retention time) value for melphalan was 6.68 min, and for dansyl 9.57 min. The extraction of melphalan from plasma and perfusate was 89%. Standard curves were generated which confirmed the accuracy of the method over the range of melphalan concentrations in plasma 0.2-200 gg ml1' (correlation coefficient, r = 0.9894). The coefficient of variation (standard deviation/mean x 100) for 20 identical samples at 2 Ig ml-' in plasma was 4.2%.
Pharmacokinetic analysis
The concentration time curves for bolus administration could be described by bi-exponential curves, fitted by the method of non-linear least squares using an 'in-house' programme based on the Marquardt algorithm (Marquardt, 1963) .
Incomplete mixing in the immediate phase after injecting the bolus of melphalan resulted in relatively wide variation in the levels measured in perfusate at the 2 min time point. These values were therefore omitted from graphical illustration and calculations.
To estimate the tissue exposure to (or bio-availability of) melphalan during isolated limb perfusion, the area under each concentration time curve was calculated for clinical and mock perfusions. The area under the curve (AUC) was calculated by the trapezoidal rule, from time zero to sixty minutes (AUCo 60) for the arterial and venous concentrations in perfusate (AUCa and AUCV). The same method was used to calculate the total AUC (AUCO -.) for systemic exposure to melphalan during and after perfusion (AUCS).
Tissue uptake of melphalan was estimated using a method based on the Fick principle (Ganong, 1981) . The amount of a substance taken up by an organ per unit of time is equal to the arterial level minus the venous level (A-V difference), multiplied by blood flow.
i.e. (1) E= (A-V) x Q when E = extraction rate, A = arterial level, V = venous level and Q = flow rate; assuming that arterial blood is the sole source of the substance. Considering a controlled system like the isolated limb perfusion circuit, the amount of substance extracted by the limb can be estimated as being equal to the extraction rate multiplied by duration of perfusion. When a series of paired arterial and venous measurements are available, the AUCa and AUCV can be introduced into the equation. i.e. for melphalan in isolated limb perfusion, (2) MELe, = E x t = (AUCa -AUCV) x Q when MEL,X = amount of melphalan extracted, E = extraction rate, t = duration of perfusion, AUCa = arterial AUC, AUCV = venous AUC, and Q = flow rate.
Assuming that Q is constant, and that MELCX is accounted for by tissue uptake alone.
Results
Perfusate versus systemic melphalan levels Illustrating the data for Group A, Figure 2 shows that the perfusate levels of melphalan are much higher than systemic levels during and after isolated limb perfusion. Pharmacokinetics and Phase I study Figure 3 shows the curves describing arterial and venous melphalan levels during isolated limb perfusion in Groups A and B. The mean arterial and venous melphalan concentration time curves for Group A and Group B can be fitted to lines described by bi-exponential equations of the form:
where Ct is concentration at time 't' minutes, A and B are intercepts on the log concentration axis at t = 0 min, of the two linear components of the curve describing logC against time, and a and P are the rate constants of these two components (Bowman & Rand, 1980) .
The values for the parameters A, B, a and P, are given in Figure 3 show that increasing the dose of melphalan from 1.5 to 1.75 mg kg' body weight resulted in higher levels of melphalan in perfusate. Comparing drug exposure in perfusate (Table I ) the values for AUCa and AUCV are both significantly greater in Group B than in Group A (P values <0.01, Mann-Whitney). The ratio AUVa/AUCs for groups B and C combined was significantly greater than for Group A (P<0.05, Mann-Whitney).
The regional toxicity for patients in the phase I study is summarised in Table III according to a simple clinical grading system-from grade I, no subjective or objective evidence of reaction to grade V, a reaction which may require amputation (Wieberdink et al., 1982) . In group B we saw Wieberdink grade III reactions on two occasions (considerable erythema and/or oedema with some blistering and slightly disturbed mobility). Since we had not seen such toxicity in either group A or in a previous pilot study of 26 patients it was decided that 1.75 mg kg-' body weight should be the maximal dose for our system. Bolus or divided dose? Figure 5 shows the curves describing melphalan concentration after bolus (Group B) or divided dose (Group C) The unit for AUC is the jig min ml-'. Toxicity: aGrade III; bGrade IV (Wieberdink et al., 1982 ).
E-,-aQ- Table IV suggest that approximately 25-40% of administered melphalan distributes to the tissues of the leg (after correction for the proportion 'lost' to the circuit) during isolated limb perfusion. The slopes of the concentration time curves after bolus dose administration (Figures 3 and 5 , Table II) indicate that melphalan disappears from perfusate more rapidly in the first half-hour of perfusion. of these values appears to be an overestimate, unless one proposes that there is very avid uptake ofmelphalan by the tissues of the leg. Hence the same calculation is applied to the 39'C mock perfusion data: MELex = (3761-3705) x 400 = 22 mg = 22% of dose, which is the proportion 'lost' to the cellular components of perfusate and to the perfusion circuit.
Discussion
Regional and systemic exposure to melphalan There have been a few studies of drug levels achieved in perfusate during ILP with melphalan (Benckhuijsen et al., 1986; Hafstrom et al., 1984; Tonak, 1981; Briele et al., 1985; Minor et al., 1985) but there is little data on systemic levels of melphalan during ILP (Hafstrom et al., 1984; Minor et al., 1985) , and the total systemic exposure to melphalan has not been quantified. In our study the peak concentrations of melphalan were much higher in perfusate than in the systemic circulation in all three groups (ratios of peak perfusate: systemic levels in tsg ml-' -A 45:0.76, B75.3:0.53, C 44:0.4).
Studies describing the pharmacokinetics of high-dose systemic intravenous melphalan (assay by HPLC) have shown mean AUC values of approximately 400 g min ml-' in adults (Stotter et al., 1987; Ardiet et al., 1986; Gouyette et al., 1986) . From Table I it can be seen that in all our patients the AUCa and AUCV are both much higher than this.
We have measured systemic melphalan levels during and for several hours after perfusion to determine the total systemic exposure (Table I) , described by the systemic AUCO <:o (AUCs). In the great majority the AUCS is much lower, being over 300 lg min ml' in only two patients. The ratio of AUCa/AUCs gives a value which describes the pharmacokinetic advantage achieved by ILP. Although there was a wide range of AUCa/AUCS, the greater values achieved with the larger dose suggest that we should use 1.75 mg kg-' rather than 1.5 mg kg-'.
Systemic exposure to melphalan-leak and washout Good surgical technique, including awareness of anatomical variations and thorough dissection of the vessels, helps to prevent sudden major 'leaks' to the systemic circulation during perfusion. Even with perfect operative technique, however, there is a variable but inevitable escape from the 'isolated' limb and this may be due to 'leakage' through intra-osseous femoral vessels, vessels passing through the obturator foramen or calcified branches of the cruciate anastomosis which may not be occluded by the tourniquet. After ILP a proportion of the melphalan taken up by the tissues of the limb may diffuse back into bloodstream and be 'washed out' into the systemic circulation.
Studies have shown, using radio-labelled albumin, that the measured 'leak' from perfusate to the systemic circulation during ILP may be as much as 40% (Lejeune & Ghanem, 1987; Hafstrom et al., 1984; Briele et al., 1985) , despite very low systemic melphalan levels during perfusion (Hafstrom et al., 1984; Lejeune & Ghanem, 1987) . On such evidence it is claimed that the radio-labelled albumin method simply overestimates the 'leak' of melphalan (Lejeune & Ghanem, 1987) but this line of argument neglects several important factors. Albumin is a relatively stable large molecule which will tend to remain within the vascular compartment. In contrast melphalan is continually degraded by hydrolysis in aqueous environments, and the fraction of melphalan which 'leaks' from the isolated limb to the systemic circulation will partition within a much larger volume of distribution (intravascular and interstitial fluid). Furthermore some of the melphalan taken up by the tissues (of the perfused leg and the rest of the body) may be protected from hydrolysis by associating with tissue proteins (Chang et al., 1978a; Ehrsson & Lonroth, 1982) and released later, when the melphalan concentration gradients are reversed after perfusion. Thus a significant fraction of the administered melphalan dose could 'leak' and be 'washed out' from the perfusate to systemic circulation, yet produce only low systemic plasma concentrations.
Pharmacokinetics of bolus administration
The concentration time curves describing melphalan in perfusate after bolus administration (Figure 3) conforming to a two compartment model. In groups A and B the ti (half-life) for the first, or a phase, was shorter than in the 1B phase. The concentration time curves for 'mock' perfusions were monophasic (Figure 4 ), conforming to a one compartment model. The ti in the ,B phase of clinical perfusion is similar to the half-life observed throughout 'mock' perfusions, when the rate of decay depends on hydrolysis plus losses in the perfusion circuit. It is inferred that the rapid loss of melphalan from perfusate in the a-phase of clinical ILP is mainly due to uptake by the tissues of the limb.
Phase I study and dosimetry To take full advantage of the potential benefit of ILP it is important that the tumour-bearing limb is subjected to the maximal safe melphalan exposure, which is a function of time and concentration and which can be quantified by the perfusate AUC. The dose of melphalan used in isolated limb varies from centre to centre. In most series the dose is calculated on the basis of body weight, and the most commonly recommended dose for an iliac perfusion is 1-1.5 mg per kilogram of body weight (Krementz, 1986; Shingleton et al., 1975; Bulman & Jamieson, 1980; Storm & Morton, 1985; Ghussen et al., 1984; Schraffordt Koops et al., 1981) . In a few studies it has been suggested that doses as high as 2 mg per kilogram of body weight can be given (Rosin & Westbury, 1980; Fontaine & Jamieson, 1974) .
There is a trend towards melphalan dosimetry for ILP according to limb volume (Krementz, 1986) . However the measurement of limb volume by water displacement (Wieberdink et al., 1982) can be a cumbersome procedure, particularly in older patients. There have been no reports describing the accuracy and reproducibility of limb volumetry by water displacement. In a small prospective study, it was found (Van Os et al., 1985) when using 10 mg 1' of limb volume that the equivalent of 1.77 mg kg-' body weight could be given safely in their patients (their previous mean dose 1.44 mg kg-'). Similar results would have been obtained in their study if the higher doses had simply been administered on the basis of body weight.
For patients of 'average build' body weight is an acceptable basis on which to calculate dose in ILP, but the use of limb volume dosimetry may be of specific value in the management of patients who have an abnormal habitus, or amputees.
It is generally accepted that a lower total dose of melphalan should be used when perfusing smaller regions of the body e.g. axillary perfusion. In this setting the limb volume method for dosimetry results in doses which are probably inadequate (Van Os et al., 1985) since they are even lower than those calculated on the basis of body weight (Krementz et al., 1985) . Although the rationale is plausible the practical benefits of routine dosimetry by limb volume are unclear.
It has been recommended that other factors to be considered when calculating the dose of melphalan to be administered include complexion and hair colour (McBride & Clark, 1971; Schraffordt Koops et al., 1977 )-fair-skinned red-heads being supposedly more susceptible to toxicity than those of a dark complexion but these recommendations have not been validated.
Body weight is obtained easily and reproducibly on the ward, without special equipment. We believed that since no formal phase I study had been carried out using body weight for dosimetry such a study should be done.
In the phase I study it was found that the dose of melphalan could be increased form 1.5 mg kg-' body weight (Group A) to 1.75 mg kg-' (Group B) with an acceptable slight increase in regional toxicity (Table III) . The peak levels of melphalan were higher after 1.75 mg kg-' than after 1.5 mg kg', and the higher levels were maintained during perfusion. Comparison of the perfusate AUC data for Groups A and B (Table I) confirms that the higher dose resulted in significantly greater bio-availability of melphalan within the limb, without any increased systemic exposure. In no patient was a significant leak suspected but there was a wide range in AUCS (8.6-402 tg min ml-'). None of the five cases which had an AUCS value greater than 200 ytg min ml-' suffered significant systemic toxicity and, in particular, there was no detected bone marrow toxicity. This may be due to the relatively slow release of melphalan from the tissues of the perfused limb, which will be less likely to produce high peak systemic levels and 'saturate' the bone marrow than a single large intravenous bolus as given during high dose systemic melphalan therapy. In reports of ILP it is remarkable that the volume of perfusate, which critically determines the effective concentration of melphalan, has been so neglected. In fact, the volume of prime is often omitted in reports (Storm & Morton, 1985; Schraffordt Keeps et al., 1987; Sugarbaker & McBride, 1976; Mikhail et al., 1984; Rege et al., 1983) , even in studies of melphalan pharmacokinetics (Hafstrom et al., 1984; Osterheld et al., 1988) .
Formerly it was believed that the perfusate volume was mainly determined by the prime (Wieberdink et al., 1982) , but the total volume of perfusate also hncludes blood trapped in the limb vessels at the start of perfusion. The volume of prime is easily measured directly but the volume of blood trapped in the limb vasculature is probably more variable. The volume of priming fluid varies in descriptions of ILP according to different authors from 600 ml (Krementz et al., 1987; Hansson et al., 1977) to two litres (Rosin & Westbury, 1980) . We used a fixed volume of prime and a standard cannulation sequence, but some of the variability in our pharmacokinetic results is likely to be due to the variable volume of trapped limb blood which contributes to the total perfusate volume.
Elegant methods have recently been described for estimating perfusate volume (Benckhuijsen et al., 1986; Lejeune & Ghanem, 1987) . The validity of these methods has not been confirmed, but the attraction is that, based on pharmacokinetic parameters, accurate knowledge of the perfusate volume would allow the administration of a dose calculated to produce a predictable concentration (Siddik et al., 1989) Once we determined that melphalan could be safely given as a bolus dose of 1.75 mg kg-' body weight (Group B, Table III ), we set out to discover whether divided dose administration at this dose level (Group C) resulted in greater AUCa and AUCV values. There was no significant difference in these values between the two groups. However one patient in Group C (total dose 175 mg; AUCa 2116 min Lg ml') suffered a severe reaction (Wieberdink Grade IV) .
We have shown that up to 165 mg of melphalan can be given safely as a bolus (calculated as 1.75 mg kg-' body weight) during ILP, and that there is no apparent pharmacokinetic advantage in divided dose administration.
Calculations of tissue uptake of melphalan It would clearly be desirable to know what proportion of administered melphalan is taken up by the tissues of the leg, and also to discover how that proportion is distributed among the different tissues (especially any differences between benign and malignant). With this knowledge the effects of various manipulations (e.g. changing dose of drug, duration of perfusion or temperature) could be assessed. Attempts have been made to estimate the proportion of administered melphalan which distributes to the tissues of the leg semi-quantitatively (Briele et al., 1985) and quantitatively (Benckhuijsen et al., 1988) . One previous publication describes the measurement of tissue concentrations of melphalan achieved by ILP (Stotter et al., 1987) in three patients. It has been suggested that cellular uptake mechanisms for melphalan may be saturable in the perfused limb (Benckhuijsen et al., 1986; Briele et al., 1985) . This is the first study where paired arterial and venous samples of perfusate were obtained for melphalan analysis throughout the hour of ILP. Hence we could use the perfusate AUC data in Formula (2) which is derived from the Fick principle. Uncorrected, the results tend to overestimate the amount of melphalan taken up by the leg (MELex) and 45-60% of administered dose. It is important to realise that the melphalan concentration measured is the plasma concentration, and that although hydrolysis is corrected for, melphalan is known to rapidly associate with the cellular components of blood (Briele et al., 1985; Greig et al., 1987 in a ratio of cells:plasma equal to approximately 1:1 (Benckhuijsen et al., 1986) . During the hour of perfusion a fraction of the administered dose (approximating to the haematocrit as %) partitions to the red blood cells, and this accounts for the 22% correction factor as calculated by applying Formula (2) to the 'mock' perfusion (see Table IV ).
Dividing the dose (Group C) may allow continued drug uptake throughout the period of perfusion but it is not clear whether this is advantageous, or whether it may be preferable to generate early high peaks by bolus administration. Yet another strategy would be to administer the cytotoxic by infusion into the arterial line of the circuit, while slowing the flow rate to maximise the effect of first-pass extraction. Homogeneous mixing of melphalan within the perfusate might be achieved by injecting the drug via the arterial line during the course of one circulation time (Wieberdink et al., 1982) .
Estimates of tissue uptake based on changes in perfusate concentration of melphalan (Briele et al., 1985; Benckhuijsen et al., 1988) , including our Fick based calculations, are merely indicators of the dynamic situation in the limb as a whole, but the critical question relates to the concentration of melphalan which is achieved at the site of action i.e. tumour cell DNA. The changes in perfusate concentration of melphalan will be, at best, crude indicators of critical events which govern the passage of melphalan from the capillary lumen to the melanoma cell nucleus. The duration of ILP with melphalan is usually one hour (Krementz et al., 1987; Martijn et al., 1986; Benckhuijsen et al., 1986 ) but it may be as short as 45 min (Mikhail et al., 1984) or as long as two and a half hours (Stehlin, 1969; Hafstrom et al., 1984) .
There is no clinical trial based evidence to suggest that the optimal duration for ILP has been found. In spite of the short half-life of melphalan in aqueous solution, and the relatively short time of exposure involved in ILP, it may be that the drug is somewhat protected from hydrolysis once it leaves the vascular compartment. Furthermore, the drug in the tissues may continue to form cross-links for hours after exposure (Hansson et al., 1987) . Hence there may be relatively little therapeutic gain achievable by prolonged clinical ILP, if maximal safe doses are already being given. We believe that it would be premature to advocate shorter periods of perfusion.
Conclusions
Isolated limb perfusion successfully and consistently achieves the aim of exposing the tumour-bearing limb to high concentrations of melphalan, while minimising systemic exposure. Following bolus administration of melphalan the concentration time curve is biphasic, with a mean ttx of 12.27-17.33 min, and mean tip of 33.4-57.17 min. Melphalan seems to be taken up by the tissues of the leg mainly during the first 30 min of isolated limb perfusion. However perfusion should last longer than 30 min to maintain the concentration gradients which drive the drug through diffusion barriers to the target cells.
In a phase I study we have shown that, using our standard technique of isolated limb perfusion, melphalan can be given safely in a bolus dose of 1.75 mg kg' body weight (up to 165 mg total dose). This higher dose yielded a significantly greater value of AUCa/AUCs than did 1.5 mg kg-.
There was no pharmacokinetic advantage in divided dose administration, and no increased regional toxicity as a consequence of the high peak levels which occur during bolus dose administration. R.N.S. was supported by a grant from the Cancer Research Campaign (SPI837).
